AR116662A2 - Formulación inmunogénica que confiere protección contra la infección o patología causada por el virus respiratorio sincicial (vrs) - Google Patents
Formulación inmunogénica que confiere protección contra la infección o patología causada por el virus respiratorio sincicial (vrs)Info
- Publication number
- AR116662A2 AR116662A2 ARP190101676A ARP190101676A AR116662A2 AR 116662 A2 AR116662 A2 AR 116662A2 AR P190101676 A ARP190101676 A AR P190101676A AR P190101676 A ARP190101676 A AR P190101676A AR 116662 A2 AR116662 A2 AR 116662A2
- Authority
- AR
- Argentina
- Prior art keywords
- rsv
- bcg
- proteins
- immunogenic
- formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 230000002163 immunogen Effects 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000007170 pathology Effects 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 3
- 230000002238 attenuated effect Effects 0.000 abstract 2
- 241000193830 Bacillus <bacterium> Species 0.000 abstract 1
- 101000833492 Homo sapiens Jouberin Proteins 0.000 abstract 1
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 abstract 1
- 102100024407 Jouberin Human genes 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 241000186359 Mycobacterium Species 0.000 abstract 1
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 abstract 1
- 101710130262 Probable Vpr-like protein Proteins 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 239000007975 buffered saline Substances 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente describe una formulación inmunogénica para ser utilizada en mamíferos contra el virus respiratorio sincicial (VRS), consistente en la cepa Bacilo de Calmette y Guerin (BCG) u otra cepa atenuada de Mycobacterium atenuado, que expresa de manera heteróloga al menos una proteína o fragmento inmunogénicos de las cepas de VRS subtipo A o VRS subtipo B, proveniente de las proteínas NS1, NS2, N, P, M, SH, M2 (ORF1), M2 (ORF2), L, F o G. El material genético que codifica para estas proteínas o fragmentos se encuentra inserto en el genoma de BCG o de manera extracromosomal en una o varias copias, cuya expresión está comandada por promotores endógenos o exógenos de BCG, constitutivos o inducibles. Las proteínas o fragmentos inmunogénicos virales pueden ser expresados por BCG de forma soluble-citoplasmática, secretada extracelularmente o como proteínas unidas a membrana celular. La preparación puede contener además combinaciones de formulaciones descritas anteriormente. La formulación puede ser estabilizada por liofilización (rango de conservación entre 4ºC y 25ºC) o por temperatura (-80ºC) en una solución salina tampón para ser conservada previo a su uso.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2007002710A CL2007002710A1 (es) | 2007-09-20 | 2007-09-20 | Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR116662A2 true AR116662A2 (es) | 2021-06-02 |
Family
ID=51399051
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104064A AR067425A1 (es) | 2007-09-20 | 2008-09-18 | Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sincicial (vrs), en una solucion salina apta para su u |
| ARP190101676A AR116662A2 (es) | 2007-09-20 | 2019-06-18 | Formulación inmunogénica que confiere protección contra la infección o patología causada por el virus respiratorio sincicial (vrs) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104064A AR067425A1 (es) | 2007-09-20 | 2008-09-18 | Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sincicial (vrs), en una solucion salina apta para su u |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8398993B2 (es) |
| EP (1) | EP2207567B1 (es) |
| CN (1) | CN101918029B (es) |
| AR (2) | AR067425A1 (es) |
| CL (1) | CL2007002710A1 (es) |
| DK (1) | DK2207567T3 (es) |
| ES (1) | ES2528197T3 (es) |
| PE (1) | PE20090653A1 (es) |
| PL (1) | PL2207567T3 (es) |
| WO (1) | WO2009039178A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102021149B (zh) * | 2010-07-27 | 2013-04-24 | 张卫东 | 基因ns1缺陷型呼吸道合胞病毒及其治疗肺癌的应用 |
| WO2013155205A1 (en) | 2012-04-10 | 2013-10-17 | The Trustees Of The University Of Pennsylvania | Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same |
| WO2014005643A1 (en) * | 2012-07-05 | 2014-01-09 | Okairos Ag | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
| CL2013002829A1 (es) * | 2013-10-01 | 2014-04-04 | Univ Pontificia Catolica Chile | Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv. |
| MX2016016533A (es) | 2014-06-13 | 2017-05-01 | Glaxosmithkline Biologicals Sa | Combinaciones inmunogenas. |
| CN104593389A (zh) * | 2015-01-27 | 2015-05-06 | 吉林大学 | 一种重组合胞病毒蛋白及其应用 |
| CL2019003847A1 (es) * | 2019-12-26 | 2021-08-06 | Univ Pontificia Catolica Chile | Nuevo uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv |
| CL2020000857A1 (es) | 2020-03-31 | 2021-11-05 | Univ Pontificia Catolica Chile | Nuevo uso de formulación inmunogénica bcg que expresa una proteína del virus respiratorio sincicial humano contra bvrs en bovinos |
| CN114748615A (zh) * | 2022-04-29 | 2022-07-15 | 成都安永鼎业生物技术有限公司 | 一种治疗用重组卡介苗的冻干制剂及其制备方法和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0590027A4 (en) * | 1991-06-13 | 1994-10-19 | Einstein Coll Med | MUTATIONS IN MYCOBACTERIES BY INSTALLATION. |
| US6566121B1 (en) * | 1991-06-13 | 2003-05-20 | Albert Einstein College Of Medicine Of Yeshiva University | Insertional mutations in mycobacteria |
| US20020081317A1 (en) * | 1999-02-02 | 2002-06-27 | Mahan Michael J. | Bacteria with altered DNA adenine methylase (DAM) activity and heterologous epitope |
| EP1305043A2 (en) * | 2000-07-31 | 2003-05-02 | Aventis Pasteur Limited | Respiratory syncytial virus vaccine |
| US7285281B2 (en) * | 2001-06-07 | 2007-10-23 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
| US7070786B2 (en) * | 2003-06-06 | 2006-07-04 | Centocor, Inc. | RSV proteins, antibodies, compositions, methods and uses |
| EP1830877A2 (en) * | 2004-12-01 | 2007-09-12 | Aeras Global TB Vaccine Foundation | Recombinant bcg strains with attenuated immunosuppresive properties |
-
2007
- 2007-09-20 CL CL2007002710A patent/CL2007002710A1/es unknown
-
2008
- 2008-09-17 WO PCT/US2008/076682 patent/WO2009039178A1/en active Search and Examination
- 2008-09-17 DK DK08832386.0T patent/DK2207567T3/en active
- 2008-09-17 ES ES08832386.0T patent/ES2528197T3/es active Active
- 2008-09-17 EP EP08832386.0A patent/EP2207567B1/en active Active
- 2008-09-17 US US12/679,091 patent/US8398993B2/en active Active - Reinstated
- 2008-09-17 CN CN200880114324.0A patent/CN101918029B/zh active Active
- 2008-09-17 PL PL08832386T patent/PL2207567T3/pl unknown
- 2008-09-18 AR ARP080104064A patent/AR067425A1/es not_active Application Discontinuation
- 2008-09-18 PE PE2008001628A patent/PE20090653A1/es active IP Right Grant
-
2019
- 2019-06-18 AR ARP190101676A patent/AR116662A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2207567B1 (en) | 2014-11-05 |
| CN101918029B (zh) | 2015-05-20 |
| CN101918029A (zh) | 2010-12-15 |
| ES2528197T3 (es) | 2015-02-05 |
| PE20090653A1 (es) | 2009-06-20 |
| CL2007002710A1 (es) | 2008-01-04 |
| DK2207567T3 (en) | 2015-01-26 |
| US8398993B2 (en) | 2013-03-19 |
| EP2207567A4 (en) | 2013-05-01 |
| PL2207567T3 (pl) | 2015-06-30 |
| EP2207567A1 (en) | 2010-07-21 |
| WO2009039178A1 (en) | 2009-03-26 |
| AR067425A1 (es) | 2009-10-14 |
| US20110200634A1 (en) | 2011-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR116662A2 (es) | Formulación inmunogénica que confiere protección contra la infección o patología causada por el virus respiratorio sincicial (vrs) | |
| WO2008085221A3 (en) | Therapeutic use of cd31 expressing cells | |
| CO6880050A2 (es) | Composiciones y metodos para controlar la fusariosis | |
| WO2007098267A3 (en) | Pseudoinfectious flavivirus and uses thereof | |
| WO2008156778A3 (en) | Influenza m2 protein mutant viruses as live influenza attenuated vaccines | |
| ECSP13010937A (es) | Compuestos antivirales | |
| WO2006122160A3 (en) | Compositions of bakuchiol and methods of making the same | |
| WO2011082388A3 (en) | Infectious dna vaccines against chikungunya virus | |
| WO2008056173A3 (en) | Pluripotent cells from the mammalian late epiblast layer | |
| JP2015525572A5 (es) | ||
| AR065076A1 (es) | Vacuna contra el papilomavirus | |
| WO2008140262A3 (en) | Use of biological surfactant as anti -inflammatory agent and tissue preservative solution. | |
| PE20090483A1 (es) | Vectores para la expresion multiple de genes | |
| WO2009036341A3 (en) | Compositions and methods relating to hiv protease inhibition | |
| BR112012028711A2 (pt) | métodos para a fabricação de uma emulsão de óleo em água, para a preparação de um kit de vacina e para redestilação de uma composição compreendendo 99% de esqualeno ou mais, assim como emulsão de óleo em água e kit | |
| NZ611531A (en) | Bovine viral diarrhea virus type 1b vaccine compositions and methods | |
| WO2012073170A3 (fr) | Composition galénique adaptée à l'administration à un animal non-humain, utilisations de celle-ci et méthodes associées | |
| WO2012135701A3 (en) | Compositions and methods for the detection of anaplasma platys | |
| CL2008003821A1 (es) | Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado | |
| WO2010064822A3 (ko) | 식물 바이러스병 방제 효과를 갖는 슈도모나스 올레오보란스 균주 | |
| WO2018115509A3 (en) | New flavivirus vaccine | |
| CL2009000791A1 (es) | Compuestos derivados de labirintopeptina; procedimiento para prepararlos que comprende fermentar la cepa actinomadura namibiensis (dsm 6313); uso de los compuestos para tratar infecciones bacterianas, infecciones viricas y/o dolor; composicion farmaceutica que los comprenden; dna que codifica la preprolabirintopeptina a2. | |
| WO2010008576A3 (en) | Idna vaccines and methods for using the same | |
| BRPI0818957B8 (pt) | gene isolado, vetor de expressão, célula hospedeira geneticamente modificada e método para preparação de uma macromolécula imunogênica | |
| NZ603854A (en) | West nile virus vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal | ||
| FC | Refusal |